Core Viewpoint - Edison Oncology Holding, a biotechnology company focused on developing targeted small molecule cancer therapies, has filed for an initial public offering (IPO) with plans to raise up to $25 million by offering 2.8 million shares at a price range of $8 to $10 per share [1] Company Overview - Edison Oncology is a clinical-stage biotechnology company dedicated to developing oncology small molecule candidates, with projects stemming from formulation improvements, repurposing existing drugs, and researching new mechanisms of action [1] - The company's product pipeline includes assets in 1-2a phase evaluations targeting ARID1A mutation cancers, replication stress pathways, ErbB-driven tumors, and pediatric solid tumors [1] Regulatory Pathways - The company is advancing its research through traditional and 505(b)(2) regulatory pathways, conducting early studies to assess safety, pharmacokinetics, and preliminary anti-tumor activity [1] Financials - For the 12 months ending September 30, 2025, the company reported revenue of $446,000 [1]